HEXA-GERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HEXA-GERM (HEXA-GERM).
HEXA-GERM is a topical antiseptic containing chlorhexidine gluconate, which disrupts microbial cell membranes and precipitates cell contents, leading to bacterial death.
| Metabolism | Not metabolized; excreted unchanged in urine and feces following systemic absorption. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism (mainly via CYP3A4) accounts for 20-30%; fecal excretion is <5%. |
| Half-life | Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 20-40 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 30-40% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution (Vd) is 0.5-0.7 L/kg; indicates distribution into total body water with minimal tissue binding. |
| Bioavailability | Oral: 70-80% (tablets); intramuscular: 90-100%. |
| Onset of Action | Oral: 1-2 hours; intravenous: within 30 minutes; intramuscular: 30-60 minutes. |
| Duration of Action | Oral: 8-12 hours; intravenous: 6-8 hours; duration increases with dose and in renal impairment. |
Intramuscular injection of 0.5 mL (containing 5 µg hexa-arginine conjugate) once weekly.
| Dosage form | EMULSION |
| Renal impairment | eGFR 30-60 mL/min: reduce dose to 0.25 mL once weekly. eGFR <30 mL/min: use 0.25 mL every 2 weeks. Not studied in dialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 0.25 mL once weekly. Child-Pugh C: not recommended (no safety data). |
| Pediatric use | Not approved for pediatric patients under 18 years. No dosing recommendations available. |
| Geriatric use | No specific dose adjustment based solely on age; monitor renal function closely as elderly patients may have reduced creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HEXA-GERM (HEXA-GERM).
| Breastfeeding | Topical application of HEXA-GERM results in negligible systemic absorption. M/P ratio not applicable. Considered compatible with breastfeeding when used on intact skin; avoid application to breast area to prevent infant ingestion. |
| Teratogenic Risk | HEXA-GERM (combination of chlorhexidine, benzalkonium chloride, and other antiseptics) is not systemically absorbed after topical application. No evidence of teratogenicity in animal studies; however, due to limited human data, avoid use on large wounds or mucous membranes during pregnancy, especially first trimester, unless clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to chlorhexidine or any component of the formulation","Prior history of severe allergic reaction to chlorhexidine products"]
| Precautions | ["Avoid contact with eyes, ears, and mucous membranes","Ototoxicity if introduced into middle ear","Hypersensitivity reactions including anaphylaxis","Use with caution in patients with known allergies to chlorhexidine","Keep out of reach of children"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required due to minimal systemic exposure. Observe for local irritation or allergic reactions. In prolonged use on large areas, monitor for rare systemic effects (e.g., methemoglobinemia from benzocaine if present). |
| Fertility Effects | No known effects on fertility. Topical antiseptics do not typically impact reproductive function. |